Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.

Abstract

One hundred and seventy six patients (81 controls, 95 receiving treatment) have entered a prospective randomized trial of long-term oral adjuvant razoxane (ICRF-159) following removal of a colorectal cancer. The median follow-up is 34 months. The treated patients in Dukes' groups B and C have a significantly longer disease-free interval than the control patients (P = 0.01 'as randomized' and P = 0.004 'as treated'). The differences in survival for Dukes' groups B and C are not significant, although follow-up is short. In Dukes' groups B and C, however, 24 of 56 of the patients in the control group have died (43%), as against only 17 of 64 in the treatment group (27%). The treatment produces very few side-effects, is well tolerated by patients, and is taken orally.

• Authors: J M Gilbert, K Hellmann, M Evans, P G Cassell, B Stoodley, H Ellis, C Wastell
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 8 Issue 3 Pg. 293-9 ( 1982) ISSN: 0344-5704 [Print] Germany
• PMID: 7127660 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antineoplastic Agents
• Piperazines
• Razoxane

Topics

• Administration, Oral
• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Colonic Neoplasms (drug therapy, mortality)
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Piperazines (therapeutic use)
• Razoxane (adverse effects, therapeutic use)
• Rectal Neoplasms (drug therapy, mortality)